# Rasagiline

## Rakinson 1mg

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | ORAK                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Indications        | ■Parkinson's disease， Initial monotherapy ■Parkinson's disease， To levodopa; Adjunct                                                                                                                                                                                                                                                                                                                                                                                                   |
| Dosing             | Monotherapy: 1 mg once daily Adjunctive therapy with levodopa: Initial: 0.5 mg once daily; may increase to 1 mg once daily based on response and tolerability                                                                                                                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Concomitant use of cyclobenzaprine， dextromethorphan， methadone， propoxyphene， St John’s wort， or tramadol; concomitant use of meperidine or an MAO inhibitor (including selective MAO-B inhibitors) within 14 days of rasagiline                                                                                                                                                                                                                                                   |
| Adverse Effects    | ■Cardiovascular: Orthostatic hypotension (6% to 9%) ■Dermatologic: Rash (3% to 6% ) ■Endocrine metabolic: Weight loss (2% to 9% ) ■Gastrointestinal: Constipation (4% to 9% )， Indigestion (7% )， Nausea (10% to 12% )， Vomiting (4% to 7%)， Xerostomia (2% to 6% ) ■Musculoskeletal: Arthralgia (6% to 11% ) ■Neurologic: Ataxia (3% to 6% )， Dyskinesia (18% )， Headache (8% to 14% ) ■Psychiatric: Depression (5% ) ■Other: Falling injury (5% )， Influenza-like illness (5% ) |
| Pregnancy          | No (limited) human data – animal data suggest risk                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                             |

